By Jaime Llinares Taboada

Shares in 4D pharma PLC rose Tuesday after it said it has received clearance from the U.S. Food and Drug Administration for clinical trials of its Live Biotherapeutic drug for the treatment of Parkinson's disease.

The pharmaceutical company said that the American regulator cleared investigational new drug, or IND, applications for Live Biotherapeutics MRx0005 and MRx0029.

First-in-human Phase I trials in people with Parkinson's disease are expected to start in mid-2022

"We believe that our LBPs MRx0005 and MRx0029, which each have different mechanisms of action worthy of investigation, provide a unique opportunity to address the high unmet needs of those living with Parkinson's disease," Chief Scientific Officer Alex Stevenson said.

Shares at 0808 GMT were up 11% at 34.0 pence.

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

(END) Dow Jones Newswires

February 22, 2022 03:33 ET (08:33 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more 4d Pharma Charts.
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more 4d Pharma Charts.